CDX2 and colorectal cancer: Existing CDX2 cut-off immunohistochemical scoring models, as discussed in Section 4.2 (Evaluation of CDX2 Expression in Colorectal Cancer), tend to oversimplify by uniformly classifying tumors as CDX2-positive, -moderate, or -negative.